 |
|
||||||||||
A new benchmark in speed, accuracy and affordability.
Human Genetic Disease Applications
The TessArae GeneCipher™ (TAGC) Assay provides unmatched speed and performance for genetic disease testing in a simple and easy to use resequencing microarray based format. Through proprietary array design and data analysis algorithms, TessArae has enabled microarray-based sequencing to finally reach its true potential, gives you the power to perform complex genetic disease testing that is FASTER, EASIER AND LESS EXPENSIVE than with conventional (Sanger) sequencing or Next-Gen sequencing technologies.
FASTER: The results you need in a fraction of the time of Sanger sequencing - The TAGC Assay is the ideal technology for resequencing hundreds of mutations in multiple genes, with turnaround times of days instead of weeks.
EASIER: : TessArae's proprietary design process, turnkey assay development, and enhanced data analysis algorithms make implementation simple - all of the development work is done for you! The scientific team collaborates with you to determine the content needed for your assay and creates the most comprehensive array and assay possible. Results are provided in 10 minutes as a list of detected mutations, eliminating the labor-intensive bioinformatics burden of Sanger and Next-Gen sequencing.
LESS EXPENSIVE: Half the cost of Sanger sequencing and significantly less than Next-Gen - As proven by several genetic disease testing organizations, The TAGC Assay lets you provide a more comprehensive test at half the cost, with virtually no gaps or areas that remain unanalyzed, minimizing the risk of missing an important genetic event.
"Implementation of the custom designed resequencing solution from TessArae, which simultaneously detects all known mutations and screens for mis-sense mutations in eight genes of the RAS/MAPK pathway, allow GeneDx to offer a more comprehensive test than we could previously, yet at significantly lower cost and with much faster turnaround time"
Dr. John Compton, GeneDx co-President, Scientific Director
